7 completed, 7 unknown, 5 recruiting, 2 active not recruiting. 8 Not applicable, 3 Phase 2, 3 Phase 3, 2 Phase 4, 1 Phase 1.
Follow Transarterial Chemoembolization: new trials by email Literature Review of Transarterial Chemoembolization trials Research Report on Transarterial Chemoembolization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma TACE-HAIC + Atezolizumab + Low-dose Bevacizumab - Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab | Not applicable | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 38 | 2026-05-01 | 2026-04-22 |
| Adjuvant TACE in HCC With High-risk Recurrence Factors Adjuvant transarterial chemoembolization, Intensive follow-up - Hepatocellular Carcinoma, Adjuvant | Phase 3 | Recruiting | Guangxi Medical University | 442 | 2026-02-01 | 2026-02-18 |
| Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma Transarterial chemoembolization (TACE), bevacizumab and atezolizumab - Hepatocellular Carcinoma, Transarterial Chemoembolization | Not applicable | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 30 | 2026-01-01 | 2025-12-15 |
| qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver qDSA Blood Flow Measurement - Transarterial Embolism, Transarterial Chemoembolization | Not applicable | Recruiting | University of Wisconsin, Madison | 20 | 2025-03-13 | 2026-09-15 |
| Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma, Relapsed and Refractory | Recruiting | Ting YANG | 10 | 2025-03-01 | 2025-11-18 | |
| Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACE Enhanced Web-Based Health Education, Routine Health Education - Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization) | Not applicable | Active not recruiting | University Medical Center Ho Chi Minh City (UMC) | 252 | 2024-09-13 | 2026-09-17 |
| TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma TACE plus camrelizumab and apatinib, Camrelizumab and apatinib - Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization | Phase 3 | Recruiting | Guohui Xu | 101 | 2024-08-10 | 2026-04-14 |
| Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma hydrochloride hydromorphone + flurbiprofen axetil, conventional analgesia - Enhanced Recovery After Surgery, Multimodal Analgesia | Phase 4 | Completed | First Affiliated Hospital, Sun Yat-Sen University | 129 | 2024-08-01 | 2026-01-02 |
| DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma DEB-TACE combined with apatinib and PD-1 antibody - Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization | Phase 2 | Completed | Sichuan Cancer Hospital and Research Institute | 20 | 2024-07-01 | 2026-04-07 |
| Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma Transarterial Chemoembolization, Systemic Therapy | Recruiting | Sun Yat-sen University | 500 | 2023-03-01 | 2025-01-23 | |
| Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization Antrodia cinnamomea, placebo - Hepatocellular Carcinoma, Transarterial Chemoembolization | Not applicable | Terminated | Taichung Tzu Chi Hospital | 23 | 2023-01-01 | 2026-10-06 |
| Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma Esketamine, Sufentanil - Hepatocellular Carcinoma, Transarterial Chemoembolization | Phase 4 | Unknown | The Second Affiliated Hospital of Chongqing Medical University | 70 | 2022-06-22 | 2023-02-24 |
| cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC Regorafenib, cTACE/DEB-TACE-HAIC - HCC, Transarterial Chemoembolization | Unknown | Peking University Cancer Hospital & Institute | 60 | 2021-09-10 | 2021-09-02 | |
| Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization DNA - Circulating Tumor DNA, Hepatocellular Carcinoma Non-resectable | Unknown | University Hospital, Rouen | 167 | 2021-05-20 | 2022-05-25 | |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC cTACE-HAIC - Transarterial Chemoembolization, Hepatocellular Carcinoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 66 | 2020-10-20 | 2020-10-22 |
| TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial TACE-HAIC plus lenvatinib - Hepatocellular Carcinoma, Transarterial Chemoembolization | Not applicable | Unknown | Yunfei Yuan | 60 | 2020-10-11 | 2021-09-22 |
| The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma lenvatinib + sindilimab/carrelizumab, TACE - Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization | Phase 1 / Phase 2 | Completed | Xinrui Zhu，MD | 142 | 2020-10-01 | 2025-08-29 |
| TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma TACE+sorafenib, TACE - Hepatocellular Carcinoma, Sorafenib | Phase 3 | Completed | Sun Yat-sen University | 162 | 2019-10-02 | 2024-02-28 |
| CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC TKI, TACE - Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization | Completed | First Affiliated Hospital, Sun Yat-Sen University | 324 | 2018-06-01 | 2026-03-04 | |
| Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging Liver resection, TACE plus Lenvatinib and PD1 inhibiter - Hepatocellular Carcinoma (HCC), Downstaging | Active not recruiting | First Affiliated Hospital, Sun Yat-Sen University | 500 | 2018-01-01 | 2026-05-14 |
Showing 20 of 24. Sign in to see all of them.
Carcinoma, Hepatocellular (15) · Cholangiocarcinoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Pain (1) · Recurrence (1)
Neoplasms (17) · Neoplasms by Histologic Type (17) · Adenocarcinoma (16) · Carcinoma (16) · Neoplasms, Glandular and Epithelial (16) · Digestive System Diseases (15) · Digestive System Neoplasms (15) · Liver Diseases (15) · Liver Neoplasms (15) · Neoplasms by Site (15) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1)
lenvatinib (3) · Bevacizumab (2) · apatinib (2) · atezolizumab (2) · camrelizumab (2) · Chemoembolization, Therapeutic (1) · DNA (1) · Doxorubicin (1) · Esketamine (1) · Gelatin Sponge, Absorbable (1) · Hepatectomy (1) · Hydromorphone (1) · Sufentanil (1) · flurbiprofen axetil (1) · regorafenib (1)
First Affiliated Hospital, Sun Yat-Sen University (3) · Peking University Cancer Hospital & Institute (2) · Sun Yat-sen University (2) · Third Affiliated Hospital, Sun Yat-Sen University (2) · Anhui Provincial Hospital (1) · Fan Weijun (1) · Guangxi Medical University (1) · Guohui Xu (1) · Hallym University Medical Center (1) · Sichuan Cancer Hospital and Research Institute (1) · Taichung Tzu Chi Hospital (1) · Tang-Du Hospital (1) · The Second Affiliated Hospital of Chongqing Medical University (1) · Ting YANG (1) · University Hospital, Rouen (1)
China (14) · France (1) · South Korea (1) · Taiwan (1) · United States (1) · Vietnam (1)
Guohui Xu (1) · Huang He, MD (1) · Jian-Hong Zhong (1) · Lei Liu, doctor (1) · Lianxin Liu, Ph.D. (1) · Ming Kuang, PhD (1) · Mingsheng Huang, M.D. & Ph.D (1) · Paul Laeseke, MD, PhD (1) · Sang Hoon Park, M.D., Ph.D. (1) · Shunjun Fu, Dr. (1) · Weijun Fan, M.D (1) · Wenzhe Fan, Dr. (1) · Xu Zhu (1)
PMID 11858978, PMID 22357901, PMID 24937669, PMID 26827847, PMID 27529160, PMID 28648803, PMID 30082086, PMID 31938928, PMID 31989907, PMID 32884990, PMID 34405295, PMID 34801630, PMID 35294089, PMID 38669783, PMID 38876786, PMID 38900435, PMID 41063733